Veralipride
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| N-[(1-allylpyrrolidin-2-yl)methyl]-5-(aminosulfonyl)-2,3-dimethoxybenzamide | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ℞ Prescription only |
| Routes | Oral |
| Identifiers | |
| CAS number | 66644-81-3 |
| ATC code | N05AL06 |
| PubChem | CID 47979 |
| UNII | S7064109UD  |
| Chemical data | |
| Formula | C17H25N3O5S |
| Mol. mass | 383.4625 g/mol |
 (what is this?) (verify) |
|
Veralipride (Agreal, Agradil) is a benzamide neuroleptic medicine indicated in the treatment of vasomotor symptoms associated with the menopause. It was first authorised for use in 1979. Veralipride has never gained approval in the United States.
On September 2006, it was withdrawn from the Spanish market. As a result, the European Commission referred the matter to the European Medicines Agency (EMA).
On July 2007, the EMA recommended the withdrawal of marketing authorisations for veralipride.[1]
See also [edit]
References [edit]
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
